Hypoxia and HIF‐1 increase S100A8 and S100A9 expression in prostate cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
S100A8 and S100A9, two heterodimer‐forming members of the cytosolic S100 Ca 2+ signaling protein family, are overexpressed in various cancer types, including prostate cancer. They act as proinflammatory danger signals when secreted to the extracellular space and are thought to play an important role during tumorigenesis, affecting inflammatory processes, proliferation, invasion and metastasis of tumor cells. Despite this fact, little is known about tumor environmental factors influencing S100A8/A9 expression. The aim of this study was to test the effect of hypoxia and its master transcriptional regulator hypoxia‐inducible factor 1 (HIF‐1) on S100A8/A9 expression. Hypoxia treatment resulted in induction of S100A8/A9 protein and mRNA expression in prostate epithelial BPH‐1 cells, the latter was also confirmed in the prostate cancer cell lines PC‐3 and DU‐145. Furthermore, overexpression of HIF‐1α caused increase in S100A8/A9 protein and mRNA expression as well as secretion. Functional hypoxia response elements mediating promoter activation on HIF‐1α overexpression were identified within the S100A8 and S100A9 promoters using promoter luciferase reporter constructs. Binding of HIF‐1α to S100A8 and S100A9 promoters was confirmed by chromatin immunoprecipitation. Immunohistochemical analysis of a prostate cancer tissue array showed clear correlation of S100A8 and S100A9 with HIF‐1α expression. Multivariate proportional hazard analysis revealed association of high S100A9 level with time to prostate cancer recurrence. In conclusion, we identified hypoxia and HIF‐1 as novel regulators of S100A8/A9 expression in prostate cancer. S100A9 might be useful as prognostic marker for prostate cancer recurrence after radical prostatectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Donato, R. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00046-2 · Cited by 1,580 · cited 1×
“S100A8 and S100A9 are two heterodimer-forming members of the S100 family of cytosolic Ca2þ binding proteins, which exhibit cell- and tissue type-specific expression.(1,2) While S100A8/A9 are constitutively expressed in myeloid cells, like neutrophils and monocytes, their expression is inducible in other cell types, fo…”
BackgroundVogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032
Boniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase
Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H., & Maru, Y. (2008) · Nature Cell Biology · doi:10.1038/ncb1794 · Cited by 642 · cited 1×
“In mouse, soluble tumorderived factors induced S100A8/A9 expression in distant organs, thereby creating a premetastatic niche and facilitating tumor spread.(14,15) Furthermore, S100A8/A9 have been reported to activate key genes of protumorigenic pathways involved in tumor progression and metastasis.”
BackgroundS100A8/A9 activate key genes and pathways in colon tumor progression
Ichikawa, M., Williams, R., Wang, L., Vogl, T., & Srikrishna, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0394 · Cited by 346 · cited 1×
“Furthermore, S100A8/A9 have been reported to activate key genes of protumorigenic pathways involved in tumor progression and metastasis.(16) Direct tumor promoting effects of S100A8/A9, like stimulation of proliferation and migration have been shown for various tumor cell lines.”
BackgroundVergis, R., Corbishley, C. M., Norman, A. R., Bartlett, J., Jhavar, S., Borre, M., Heeboll, S., Horwich, A., Huddart, R., Khoo, V., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70076-7 · Cited by 282 · cited 2×
“Exclusive nuclear staining of HIF-1a was scored as intensity 1, in accordance with reports that cytoplasmic staining is a more important predictor for outcome.(25)”
BackgroundMethod
Cited by
Bresnick, A. R., Weber, D. J., & Zimmer, D. B. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3893 · Cited by 822
S100A8/A9: From basic science to clinical application
Pruenster, M., Vogl, T., Roth, J., & Sperandio, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.015 · Cited by 450
Chen, Y., Ouyang, Y., Li, Z., Wang, X., & Ma, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188891 · Cited by 165
Robust shifts in S100a9 expression with aging: A novel mechanism for chronic inflammation
Swindell, W. R., Johnston, A., Xing, X., Little, A., Robichaud, P., Voorhees, J. J., Fisher, G., & Gudjonsson, J. E. (2013) · Scientific Reports · doi:10.1038/srep01215 · Cited by 124
Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3890 · Cited by 76
Metadata
- Authors
- Grebhardt, S., Veltkamp, C., Ströbel, P., & Mayer, D.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-05-08
- Volume
- 131
- Issue
- 12
- Pages
- 2785-2794
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2054936631
- Cited by
- 81
- References
- 8
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.